Skip to main content
SpringerLink
Log in

Improvements of quality of life in patients with advanced non-small cell lung cancer treated with gefitinib

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of this study was to evaluate the effect of gefitinib on improvement of quality of life (QoL) of patients with advanced non-small cell lung cancer (NSCLC).

Methods

There were 70 patients with advanced NSCLC. One oral gefitinib tablet (250 mg) was administered every day without interruption unless disease progression or unacceptable toxicity occurred. The impact of treatment on disease-related symptoms and QoL was evaluated with the Chinese versions of European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and QLQ-LC13).

Results

Fifty-eight patients had finished the questionnaires. The mean scores of five functioning scales (physical, role, emotional, cognitional and social) were 62.64, 56.03, 68.41, 64.67, 60.63 respectively after eight weeks of treatment, which were 52.30, 49.43, 64.39, 59.79, 52.30 respectively before treatment, and the mean score of global QoL after and before treatment was 60.17 and 52.70 respectively. There was statistical difference in five functioning scales and global QoL (P < 0.05). Mean scores of main general symptoms (fatigue and appetite loss) were 57.66 and 48.08 respectively after eight weeks of treatment, which were 61.11 and 51.72 respectively before treatment, and mean scores of disease-related symptoms (dyspnoea, coughing, empsyxis, pain in chest) were 48.66, 47.13, 26.82, 24.71 respectively after eight weeks of treatment, which were 54.98, 53.64, 27.78, 28.54 respectively before treatment. There was statistical difference in fatigue, dyspnoea, cough and pain in chest (P < 0.05). Response rate of five functioning and global QoL were all more than 50% after gefitinib treatment. Response rate of main general symptoms and disease-related symptoms were all more than 40%. QoL and symptom response correlated with disease control. The patients with better QoL had longer survival.

Conclusion

gefitinib treatment can improve the QoL and symptoms of advanced NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zhou QH, Wang J, Xu F. Clinical guideline of non-small cell lung cancer in 2005 national comprehensive cancer network. Chin J lung Cancer (Chinese), 2005, 8: 332–346.

    Google Scholar 

  2. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993, 85: 365–376.

    Article  PubMed  CAS  Google Scholar 

  3. Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer, 1999, 79: 538–544.

    Article  PubMed  CAS  Google Scholar 

  4. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest, 1998, 113: 467–481.

    Article  PubMed  CAS  Google Scholar 

  5. Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9: 129–137.

    Article  PubMed  CAS  Google Scholar 

  6. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL1 Trial). J Clin Oncol, 2003, 21: 2237–2246.

    Article  PubMed  CAS  Google Scholar 

  7. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290: 2149–2158.

    Article  PubMed  CAS  Google Scholar 

  8. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol, 2003, 30: 30–38.

    Article  PubMed  CAS  Google Scholar 

  9. Cella D. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale. Semin Oncol, 2003, 30: 39–48.

    Article  PubMed  CAS  Google Scholar 

  10. Guang ZZ, Zhang L, Li LY. Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial. Cancer (Chinese), 2005, 24: 980–984.

    Google Scholar 

  11. Zhang K, Zuo Q, Luo RC. Efficacy of Gefitinib in 36 patients with advanced non-small cell lung cancer. Chin Oncol (Chinese), 2006, 16: 878–879.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Yanmei Zou, Hua Xiong & Shiying Yu

Authors
  1. Yanmei Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hua Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shiying Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hua Xiong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zou, Y., Xiong, H. & Yu, S. Improvements of quality of life in patients with advanced non-small cell lung cancer treated with gefitinib. Chin. -Ger. J. Clin. Oncol. 8, 495–497 (2009). https://doi.org/10.1007/s10330-009-0116-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-009-0116-5

Key words

Search

Navigation